Jasper Therapeutics is a clinical-stage biotechnology company advancing antibody therapies for mast cell–driven diseases and, following its July 2026 acquisition of Kira Pharmaceuticals, kidney-focused programs. The third-quarter 2026 report is notable because it is the first to include Kira's contributions, introducing a meaningful revenue line to a company that historically operated with little to no product revenue. For investors, the update offers an early read on how the combined pipeline and balance sheet are performing after a transformative M&A period. Prior quarters were defined by clinical data updates and capital raises; this quarter shifts the focus toward integration, a deeper reported loss, and near-term data milestones that could shape the company's clinical direction.
For the third quarter of 2026, JSPR reported revenue of $8.0 million and a net loss of $144.5 million, or $10.19 per basic and diluted share. Research and development (R&D) expense was $8.3 million, while general and administrative (G&A) expense was $6.4 million. Cash and cash equivalents stood at $135.3 million as of September 30, 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The per-share loss came in materially wider than the consensus estimates compiled by financial data providers, which had generally anticipated a much smaller loss per share. The revenue figure, by contrast, compared favorably with some estimates and reflected the first full-period contribution from the Kira Pharmaceuticals acquisition. The company also disclosed that it completed enrollment in the first IgA nephropathy cohort of its Phase 2 renal basket study of vensobafusp alfa and expects to report interim Stage 1 data in the fourth quarter of 2026. Supporting the balance sheet, a related private placement closed in July generated approximately $132.0 million in gross proceeds, and the company effected a 1-for-30 reverse stock split in November 2026.
Investor reaction to Jasper's quarterly earnings has been shaped more by the pipeline narrative than by the headline financial figures. The sharply wider net loss was widely anticipated to reflect acquisition-related costs, and attention instead gravitated toward the integration of Kira Pharmaceuticals and the upcoming vensobafusp alfa data readouts. The November 1-for-30 reverse stock split also complicates straightforward share-price comparisons, making short-term price moves less informative than usual. Sentiment remains cautious given the company's status as a pre-commercial biotech with ongoing clinical execution risk, but the expanded pipeline and strengthened cash position have provided a measure of balance-sheet comfort heading into the next data events.
Looking ahead, the most important catalyst for Jasper Therapeutics is the interim Stage 1 data from the Phase 2 renal basket study of vensobafusp alfa in IgA nephropathy, which management expects to report in the fourth quarter of 2026. These results will help investors assess whether the Kira acquisition can generate clinically meaningful value beyond the revenue contribution already reflected in the third quarter.
Investors should also monitor how the combined organization manages its cost structure. The jump in the reported net loss highlights the financial weight of integration and ongoing development, so expense discipline and the pace of cash burn will remain closely watched against the $135.3 million cash balance. Any additional financing activity, given the recent private placement and reverse split, would be another key signal.
Finally, keep an eye on enrollment progress and updates across Jasper's mast cell disease programs, including chronic urticaria, as the company works to establish a clearer regulatory path. None of this constitutes a prediction of share-price direction, but these milestones will likely define how investors interpret the next several quarters of quarterly earnings.
In my analysis of recent biotech movers, I turned to Tickeron’s AI Screener to filter for companies with similar acquisition-driven revenue shifts and upcoming clinical catalysts. The tool allowed me to quickly scan technical patterns and fundamentals across the sector, helping refine my focus on integration risks and data timelines without manual effort. It has become a regular part of my workflow for identifying comparable names and monitoring volatility around earnings.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
JSPR saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned negative. In 84 of the 92 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for JSPR turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 34 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JSPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for JSPR entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +6.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where JSPR advanced for three days, in 203 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
JSPR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. JSPR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: JSPR's P/B Ratio (397.034) is very high in comparison to the industry average of (3.498). P/E Ratio (-18.129) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JSPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology